VisionGate

VisionGate, Inc. is a privately held company based in Phoenix, Arizona, with a team of 25 employees. VisionGate develops and markets liquid biopsy technology focused on early cancer detection. Their core product, the LuCED® lung test, is a non-invasive sputum-based test designed to identify lung cancer and bronchial dysplasia. The test utilizes the company's proprietary Cell-CT™ 3-Dimensional Cell Imaging and Analysis platform, which employs optical computed tomography (CT) to generate 3D images of individual cells, allowing for the recognition of over 700 structural biomarkers. The Cell-CT platform's potential extends beyond lung cancer detection. Its ability to process various liquid biopsy specimens suggests applications in identifying a range of cancers and biosignatures, potentially aiding in the development of targeted pharmaceutical therapies. VisionGate is also developing the CellGazer™ application, an imaging software tool designed to assist cytopathologists in diagnosing abnormal cells detected by the Cell-CT platform. For more information, please visit www.visiongate3d.com.